Gina Tomaine

News

Teclistamab Induces Deep and Durable Responses in Triple–Class-Exposed Relapsed/Refractory MM

07/13/2022

Teclistamab, a T-cell–redirecting bispecific antibody, showed promising efficacy in treating patients with triple-class–exposed relapsed or refractory MM, inducing deep and durable responses in a recent study.

Teclistamab, a...

07/13/2022

Oncology

News

FDA Grants Expedited Approval to Quizartinib for Patients With Newly Diagnosed AML With FLT3/ITD Mutations

07/24/2023

Gina Tomaine ;

The FDA granted approval to quizartinib for patients with newly diagnosed FLT3/ITD-positive acute myeloid leukemia, as detected by an FDA-approved test.

The FDA granted approval to...

07/24/2023

Oncology

News

Ibrutinib Plus Bendamustine and Rituximab Prolongs PFS in Older Patients with MCL

08/02/2022

Gina Tomaine ;

Ibrutinib added to bendamustine and rituximab followed by rituximab maintenance yields significantly longer PFS vs placebo in older patients with previously untreated MCL, according to findings from the phase 3 SHINE trial.

Ibrutinib added to bendamustine...

08/02/2022

Oncology

News

Jaktinib Improves Clinical Symptoms in JAK Inhibitor-Naïve Patients With Myelofibrosis

09/20/2022

Gina Tomaine ;

Jaktinib reduces spleen volume and improves anemia and other clinical symptoms with acceptable tolerability in JAK inhibitor-naïve patients with myelofibrosis, according to results from a phase 2 trial.

Jaktinib reduces spleen volume...

09/20/2022

Oncology

News

PILOT Trial Supports Lisocabtagene Maraleucel as Second-Line Therapy for Relapsed/Refractory LBCL

09/02/2022

Gina Tomaine ;

Lisocabtagene maraleucel demonstrates promising safety and efficacy as a second-line treatment for patients with LBCL not eligible for hematopoietic stem-cell transplantation, according to findings from the PILOT trial.

Lisocabtagene maraleucel...

09/02/2022

Oncology

News

CD19 CAR T-Cell Product Type Impact on Outcomes in Relapsed/Refractory Non-Hodgkin Lymphoma

08/02/2022

Gina Tomaine ;

Study findings suggest that CD19 CAR T-cell product type, among axicabtagene ciloleucel, tisagenlecleucel, and JCAR014, independently impacts toxicity and efficacy in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Study findings suggest that CD19...

08/02/2022

Oncology

News

MRD-Guided Quadruplet Regimen Associated With Deep, Durable Responses in MM

08/10/2022

Gina Tomaine ;

An MRD-adapted study design using elotuzumab with weekly carfilzomib, lenalidomide, and dexamethasone without transplant was associated with deep, durable responses in patients with MM.

An MRD-adapted study design...

08/10/2022

Oncology

News

Evaluating Long-Term Clinical Efficacy of ESAs Among Patients With Low‑Risk or Intermediate‑1‑Risk MDS

09/11/2023

Gina Tomaine ;

Erythropoiesis‑stimulating agent efficacy began to plateau after the 24th month of therapy among patients with low‑risk or intermediate‑1‑risk MDS, followed by a decrease in response rates, according to data presented at the SOHO 2023 annual...

Erythropoiesis‑stimulating agent...

09/11/2023

Oncology

News

Momelotinib Associated With Positive Survival Outcomes in Patients With Myelofibrosis: SIMPLIFY Trials

08/04/2022

Gina Tomaine ;

In the phase 3 SIMPLIFY trials, momelotinib demonstrated excellent OS and leukemia-free survival in patients with myelofibrosis, as well as activity against anemia, symptoms, and splenomegaly.

In the phase 3 SIMPLIFY trials,...

08/04/2022

Oncology

News

Long-Term Results of ASCT in Adult High-Risk Acute Lymphoblastic Leukemia

09/13/2022

Gina Tomaine ;

Matched sibling and unrelated donor-based allogeneic hematopoietic stem cell transplantations in patients with BCR-ABL-negative acute lymphoblastic leukemia yielded similar long-term outcomes.

Matched sibling and unrelated...

09/13/2022

Oncology